舒尼替尼治疗晚期肾癌的预后因素分析及国际转移性肾细胞癌数据库联盟预后模型验证.pdfVIP

668JMoUrol,Vol.26No.8Aug.2021

•临床研(•

舒尼替尼治疗晚期肾癌的预后因素分析及国际转移性肾细胞癌数据库联

盟预后模型验证

周饶饶1!,戚聂聂？，赵方正1!,李子祥1!,王诗驿1!,邱冬1,王军起？，朱海涛？

(1徐州医科大学研究生院，江苏徐州221000.徐州医科大学附属医院泌尿外科，江苏徐州221002)

PrognosticfactorsofsurvivalandverificationoftheprognosticmodelofIMDCin

patientswithmetastaticrenalcellcarcinomtreatedwithsunitinib

ZHOURaorao12,QINienie1,ZHAOFangzheng12,LIZixiang12,WANGShiyi1，,QIUDong1,

WANGJunqi1,ZHUHaitao1

(1.GraduateSchool,XuzhouMedicalUniversity,Xuzhou221000；2.DepartmentofUrology,AffiliateHos-

pitalofXuzhouMedicalUniversity$Xuzhou221002$China)

ABSTRACT:ObjectiveToexploretheprognosticfactorsofmetastaticrenalcellcarcinoma(mRCC)treatewth

suni$iniband$overify$heaccuracyof$heIn$erna$ionalMe$as$a$icRenal-CelCarcinomaDa$abaseConsor$ium(IMDC)prog-

nos$icmodel.MethodsClinicalda$aof115pa$ien$swi$hadvancemRCC$rea$ewi$hsuniinibwerecolec$ed.Thesurvival

curvewasplottewithKaplan-Meiermethod.SignificancewastestewthLog-rank.Univariateanmultivariateanalyseswere

performewithCoxproportionalhazardsregressionmodel.ThepredictiveabiltyofthemodelwasverifieusingHarrellcon-

cordanceindex.ResultsMedianfolow-upwas14.6(2—54)months$anmedianprogresion-freesurvivalwas11.3(9.4—

13.2)months.UnivariateanalysisshowethatECOGperformancestatus,IMDCstratification,numberofmetastaticsites,bone

metastasis,livermetastasis,relativedoseintensityinthefirstmonth(1M-RDI)50%,hand-footsyndrome(HFS)3,neutro-

phil-to-lymphocyteratio(NLR%,anclinicalsymptomsatinitialdiagnosiswereprognostic6actorso6mRCC.Multivariatere­

gressionanalysisshowethatECOGperformancestatus2,IMDChighrating,numberofmetastaticsitesX,NLR2.7,and

clinical(ymptom(atinitialdiagno(i(wereindependentri(kfactor(fortheprogn